Advertisement

Topics

NICE backs Strensiq for some HPP patients

14:27 EDT 22 Sep 2016 | BioCentury

The U.K.'s NICE issued draft guidance recommending approval of Strensiq asfotase alfa from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat the bone manifestations of perinatal- and infantile-onset hypophosphatasia as part of a managed access agreement.

The recommendation covers patients whose onset of the disease occurs before six months of age. The drug is approved in Europe for that population as well as juvenile-onset HPP, which includes patients with disease onset prior to 18 years of age.

The recommendation is contingent on Alexion providing Strensiq under a discount scheme that includes an undisclosed maximum cost cap per patient. Alexion is also to "provide further opportunities to reduce the short-term cost" of Strensiq to the NHS, the guidance said.

Strensiq is a fusion protein incorporating the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP; ALPL) and a bone-targeting peptide. According to NICE, its cost varies from L165,000 ($215,457) for a baby to L1.5 million ($2 million) for an 80 kg adult, based on its list price. Comments on the draft guidance are due Oct. 13.

In December guidance, NICE recommended against Strensiq's use. At the time, the committee had said there was "considerable uncertainty around the robustness" of clinical results and natural history data, as well as the "precise size" of the drug's benefit.

Alexion gained $3.33 to $133.69 on Thursday.

Original Article: NICE backs Strensiq for some HPP patients

NEXT ARTICLE

More From BioPortfolio on "NICE backs Strensiq for some HPP patients"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...